<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dopamine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dopamine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dopamine: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="12207" href="/d/html/12207.html" rel="external">see "Dopamine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13248" href="/d/html/13248.html" rel="external">see "Dopamine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F162703"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Adrenergic Agonist Agent;</li>
<li>
                        Inotrope</li></ul></div>
<div class="block doa drugH1Div" id="F162660"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Hemodynamic effects of dopamine are dose dependent (however, this is relative and there is overlap of clinical effects between dosing ranges) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21097695','lexi-content-ref-28101605','lexi-content-ref-32820475']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21097695','lexi-content-ref-28101605','lexi-content-ref-32820475'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Low dose: Augments renal dopamine receptors, which may increase renal blood flow and urine output. The use of low-dose dopamine to prevent or treat acute kidney injury is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">Intermediate dose: Dopamine and beta-adrenergic effects predominate, resulting in increased renal blood flow, heart rate, cardiac contractility, and cardiac output.</p>
<p style="text-indent:-2em;margin-left:4em;">High dose: Alpha-adrenergic effects begin to predominate, resulting in vasoconstriction and increased blood pressure, in addition to increased heart rate, cardiac contractility, and cardiac output due to beta-adrenergic effects.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="18ae4661-ec31-4c3c-83c5-d332e4c822f2">Bradycardia or atrioventricular block, symptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bradycardia or atrioventricular block, symptomatic (unresponsive to atropine) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous infusion:</b>
<b>IV: </b>Initial: 5 mcg/kg/minute; increase by 5 mcg/kg/minute every 2 minutes until desired effect; maximum dose: 20 mcg/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30412709','lexi-content-ref-33081529','lexi-content-ref-AHA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30412709','lexi-content-ref-33081529','lexi-content-ref-AHA.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e09015f4-003d-4126-9410-366d4a3243fe">Hypotension or shock</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypotension or shock:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Cardiogenic shock </b>
<b>(alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Typically, not the preferred initial agent in cardiogenic shock; consider other inotropic and/or vasopressor options; caution with the use of dopamine due to increased arrhythmias and possibly mortality in this population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28923988','lexi-content-ref-20200382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28923988','lexi-content-ref-20200382'])">Ref</a></span>). Optimal goal of therapy not well established, but typically titrate to maintain end-organ perfusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28923988']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28923988'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Continuous infusion:</b>
<b>IV: </b>Usual dosage range: 0.5 to 20 mcg/kg/minute; titrate based on clinical end point (eg, end-organ perfusion) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28923988']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28923988'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Septic shock and other vasodilatory shock states (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b>
<b>Not</b> recommended for septic shock <i>except</i> as an alternative to norepinephrine in patients with bradycardia who have a low risk of tachyarrhythmias (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34605781','lexi-content-ref-28101605']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34605781','lexi-content-ref-28101605'])">Ref</a></span>). Compared to norepinephrine, dopamine is associated with an increased risk of tachyarrhythmias and potentially worse outcomes (eg, increased mortality, kidney failure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26237037','lexi-content-ref-22036860','lexi-content-ref-34605781','lexi-content-ref-28101605']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26237037','lexi-content-ref-22036860','lexi-content-ref-34605781','lexi-content-ref-28101605'])">Ref</a></span>). In general, maintain goal mean arterial pressure (MAP) (eg, ~65 mm Hg); consider use if patient is in shock or has hypoperfusion during or after fluid resuscitation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23353941','lexi-content-ref-29767636','lexi-content-ref-28101605']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23353941','lexi-content-ref-29767636','lexi-content-ref-28101605'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Continuous infusion:</b>
<b>IV: </b>Initial: 2 to 5 mcg/kg/minute; titrate to goal MAP up to a dose of 20 mcg/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20200382','lexi-content-ref-Manaker.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20200382','lexi-content-ref-Manaker.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Post–cardiac arrest shock (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Typically, not the preferred initial agent in post–cardiac arrest shock due to risk of tachyarrhythmias; consider other inotropic and/or vasopressor options (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20200382','lexi-content-ref-32820475']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20200382','lexi-content-ref-32820475'])">Ref</a></span>). Optimal goal of therapy is not well established, but typically titrate to MAP &gt;65 mm Hg and preferably &gt;80 mm Hg to optimize cerebral and end-organ perfusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26472996','lexi-content-ref-32820475']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26472996','lexi-content-ref-32820475'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Continuous infusion:</b>
<b>IV: </b>Usual dosage range: 5 to 20 mcg/kg/minute; titrate based on clinical end points (eg, MAP, end-organ perfusion) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956225','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956225','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="69341349-2ce2-472f-af23-cc4f03c9b01e">Inotropic support</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Inotropic support:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> May consider in patients with severe systolic dysfunction with decreased end-organ perfusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Continuous infusion:</b>
<b>IV: </b>5 to 15 mcg/kg/minute; doses at lower end of this range are preferred as inotropic actions predominate at lower doses and vasoconstrictive actions predominate at higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-21097695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-21097695'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block doo drugH1Div" id="F56844708"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">The recommendations for dosing in patients with obesity are based upon the best available evidence and clinical expertise. Senior Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Class 1, 2, and 3 obesity (BMI ≥30 kg/m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous infusion: IV:</b> Use <b>ideal body weight</b> for initial dose calculations, then titrate to hemodynamic effect and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33622380','lexi-content-ref-Expert.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33622380','lexi-content-ref-Expert.1'])">Ref</a></span>). During therapy, clinicians should <b>not</b> change dosing weight from one weight metric to another (ie, ideal body weight to/from actual body weight) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33622380','lexi-content-ref-Expert.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33622380','lexi-content-ref-Expert.1'])">Ref</a></span>). Refer to adult dosing for indication specific doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rationale for recommendations:</b></p>
<p style="text-indent:-2em;margin-left:4em;">There is a paucity of studies evaluating the influence of obesity on dopamine dosing or pharmacokinetics. One observational study evaluating patients with obesity and overall mortality showed a trend in lower dopamine doses at 6 hours with increasing obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23594407']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23594407'])">Ref</a></span>). Other observational studies, including phenylephrine, epinephrine and norepinephrine, suggest non–weight-based dosing strategies may result in lower overall cumulative dose requirements and increased drug exposure to second line agents in some patients and may not be advantageous in time to achieving hemodynamic stability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27969574','lexi-content-ref-26724290','lexi-content-ref-27886982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27969574','lexi-content-ref-26724290','lexi-content-ref-27886982'])">Ref</a></span>). However, it is difficult to show outcome differences between weight-based and non–weight-based dosing because of dose titration to target BP, particularly in the context of retrospective studies. Furthermore, there is substantial variability in response in critically ill patients, irrespective of weight. Due to the short onset of action and small volume of distribution, rapid titration to clinical effect after initial dosing is possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33622380']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33622380'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F162661"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F162681"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13248" href="/d/html/13248.html" rel="external">see "Dopamine: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0aaecd9a-fa24-4a15-9c5b-a253afdc5ee0">Hemodynamic support</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodynamic support:</b> Infants, Children, and Adolescents: Continuous IV or intraosseous infusion: 2 to 20 mcg/kg/minute; titrate gradually by 5 to 10 mcg/kg/minute increments until optimal response is obtained (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956230','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956230','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> Dopamine has a dose-dependent effect; doses at lower end of this range are preferred, as inotropic actions predominate at lower doses and vasoconstrictive actions predominate at higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28509730','lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28509730','lexi-content-ref-20956230'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F162628"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris, atrial fibrillation, bradycardia, cardiac conduction disorder, ectopic beats, hypertension, hypotension, palpitations, tachycardia, vasoconstriction, ventricular arrhythmia, widened QRS complex on ECG</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Peripheral gangrene (with prolonged or high dose, can occur with low doses with concomitant occlusive vascular disease), piloerection</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Azotemia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, headache</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea</p></div>
<div class="block coi drugH1Div" id="F162643"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Pheochromocytoma.</p></div>
<div class="block war drugH1Div" id="F162626"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Arrhythmias: May cause increases in heart rate, increasing the risk of tachycardia and other tachyarrhythmias including ventricular arrhythmias (Tisdale 1995). In heart transplant candidates, institute appropriate measures to protect patient against risks of sudden cardiac death (Young 2000).</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation; infuse into a large vein if possible. Avoid infusion into leg veins. Watch IV site closely. If extravasation occurs, infiltrate the area with diluted phentolamine (5 to 10 mg in 10 mL of saline) with a fine hypodermic needle. Phentolamine should be administered as soon as possible after extravasation is noted to prevent sloughing/necrosis (Stefanos 2023).<b></b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease, cardiac arrhythmias and/or occlusive vascular disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Active myocardial ischemia/post-myocardial infarction: Use with caution in patients with active myocardial ischemia or recent myocardial infarction; may increase myocardial oxygen consumption.</p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy to minimize the risk of arrhythmias (ACC/AHA/ESC [Zipes 2006]; Tisdale 1995).</p>
<p style="text-indent:-2em;margin-left:4em;">• Shock: The use of dopamine in adult patients with shock (majority of patients had septic shock) demonstrated a higher incidence of adverse events (eg, tachyarrhythmias) (De Backer 2010). Higher 28-day mortality was also seen in patients with septic shock with the use of dopamine as compared to norepinephrine (De Backer 2012; Vasu 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium metabisulfite: Product may contain sodium metabisulfite.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Assure adequate circulatory volume to minimize need for vasoconstrictors when used in hemodynamic support. Avoid hypertension; monitor blood pressure closely and adjust infusion rate.</p></div>
<div class="block foc drugH1Div" id="F162636"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.8 mg/mL (250 mL, 500 mL); 1.6 mg/mL (250 mL, 500 mL); 3.2 mg/mL (250 mL); 40 mg/mL (5 mL, 10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg/mL (5 mL, 10 mL)</p></div>
<div class="block geq drugH1Div" id="F162622"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323119"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (DOPamine HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/mL (per mL): $0.70 - $0.92</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (DOPamine in D5W Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.8 mg/mL 5% (per mL): $0.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.6 mg/mL 5% (per mL): $0.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3.2 mg/mL 5% (per mL): $0.09 - $0.10</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866657"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.8-5 MG/ML-% (250 mL); 1.6-5 MG/ML-% (250 mL, 500 mL); 3.2-5 MG/ML-% (250 mL, 500 mL)</p></div>
<div class="block adm drugH1Div" id="F162640"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b>
<b>Administer as a continuous infusion via an infusion pump.</b> Central line administration is preferred; extravasation may cause severe ischemic necrosis. If central line is not available, may administer for a short duration (&lt;72 hours) through a peripheral IV catheter placed in a large vein at a proximal site (eg, in or proximal to antecubital fossa). Frequent monitoring of the IV catheter site is recommended to rapidly identify extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26014852','lexi-content-ref-34605781','lexi-content-ref-28073314','lexi-content-ref-29110979','lexi-content-ref-31698544']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26014852','lexi-content-ref-34605781','lexi-content-ref-28073314','lexi-content-ref-29110979','lexi-content-ref-31698544'])">Ref</a></span>). Refer to institutional policies and procedures; catheter placement/size and vasopressor concentration may vary depending on institution.</p>
<p style="text-indent:0em;margin-top:2em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately; leave cannula/needle in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry, warm compresses; initiate phentolamine (or alternative) antidote (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Phentolamine:</i>
<b>SUBQ: </b>Dilute 5 to 10 mg in 10 mL NS and administer into extravasation site as soon as possible after extravasation; if IV catheter remains in place, administer initial dose intravenously through the infiltrated catheter; may repeat in 60 minutes if patient remains symptomatic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Alternatives to phentolamine:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Nitroglycerin topical 2% ointment: Apply a 1-inch strip to the site of ischemia to cover the affected areas; may repeat every 8 hours as necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Terbutaline:</p>
<p style="text-indent:-2em;margin-left:8em;">Large extravasations: <b>SUBQ: </b>Infiltrate affected extravasation area with terbutaline 1 mg using a solution of terbutaline 1 mg diluted in 10 mL NS; may repeat dose after 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Small extravasations: <b>SUBQ: </b>Infiltrate affected extravasation area with 0.5 mg using a solution of terbutaline 1 mg diluted in 1 mL NS; may repeat dose after 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52612622"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Continuous IV infusion: Vials (concentrated solution) must be diluted prior to administration; premixed IV solutions (800 mcg/mL, 1,600 mcg/mL, 3,200 mcg/mL) are available. Administer as a continuous IV infusion with the use of an infusion pump or an intraosseous infusion until IV access can be obtained in pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956230'])">Ref</a></span>). Administer into large vein to minimize the possibility of extravasation (central line administration); administration into an umbilical arterial catheter is <b>not </b>recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Domonoske.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Domonoske.1'])">Ref</a></span>). If central line is not available, may administer for a short duration through a peripheral IV catheter placed in a large vein or via intraosseous access using a more dilute solution or with a second carrier fluid; once central access is available, begin central line infusion and wait for pharmacologic effect prior to stopping peripheral administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-28509730','lexi-content-ref-32032273']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-28509730','lexi-content-ref-32032273'])">Ref</a></span>). Frequent monitoring of the IV catheter site is recommended to rapidly identify extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24420913'])">Ref</a></span>). Refer to institutional policies and procedures; catheter placement/size and vasopressor concentration may vary depending on institution. Do not administer sodium bicarbonate (or any alkaline solution) through an IV line containing dopamine; inactivation of dopamine may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244'])">Ref</a></span>). Avoid abrupt discontinuation; reduce infusion flow rate slowly.</p>
<p style="text-indent:-2em;margin-left:2em;">Rate of infusion (mL/hour) = [dose (mcg/kg/minute) × weight (kg) × 60 minutes/hour] divided by concentration (mcg/mL)</p>
<p style="text-indent:-2em;margin-left:2em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Initiate phentolamine (or alternative) antidote (see Management of Drug Extravasations for more details). Apply dry warm compresses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15192356','lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15192356','lexi-content-ref-24420913'])">Ref</a></span>).</p></div>
<div class="block uica drugH1Div" id="F14471801"><span class="drugH1">Usual Infusion Concentrations: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premixed solutions available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV infusion:</b> 400 mg in 250 mL (concentration: 1600 <b>mcg</b>/mL) <b>or</b> 800 mg in 250 mL (concentration: 3200 <b>mcg</b>/mL)  of D<sub>5</sub>W or NS </p></div>
<div class="block uicp drugH1Div" id="F14471802"><span class="drugH1">Usual Infusion Concentrations: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premixed solutions available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV infusion:</b> 800 <b>mcg</b>/mL, 1,600 <b>mcg</b>/mL, <b>or</b> 3,200 <b>mcg</b>/mL.</p></div>
<div class="block use drugH1Div" id="F162639"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Hypotension or shock:</b> Treatment of severe hypotension or shock (eg, septic shock and other vasodilatory shock states, cardiogenic shock, decompensated heart failure, post–cardiac arrest) that persists during and after adequate fluid volume replacement.</p></div>
<div class="block off-label drugH1Div" id="F25725326"><span class="drugH1">Use: Off-Label: Adult</span><p>Bradycardia or atrioventricular block, symptomatic (unresponsive to atropine)</p></div>
<div class="block mst drugH1Div" id="F162712"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">DOPamine may be confused with DOBUTamine, Dopram</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299227"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of COMT, OCT1, OCT2</p></div>
<div class="block dri drugH1Div" id="F162630"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bretylium: May enhance the therapeutic effect of Alpha-/Beta-Agonists (Direct-Acting).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Management: Consider alternatives to this combination when possible. If combined, monitor for hypertension and tachycardia, and do not coadminister these agents for more than 10 days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroprocaine (Systemic): May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: May diminish the therapeutic effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COMT Inhibitors: May increase the serum concentration of COMT Substrates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): May enhance the vasoconstricting effect of Alpha-/Beta-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Do not use hyaluronidase to enhance the dispersion or absorption of alpha-/beta-agonists. Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhalational Anesthetics: May enhance the arrhythmogenic effect of DOPamine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Landiolol: DOPamine may diminish the therapeutic effect of Landiolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of DOPamine. Management: Initiate dopamine at no greater than one-tenth (1/10) of the usual dose in patients who are taking (or have taken within the last 2 to 3 weeks) monoamine oxidase inhibitors. Monitor for an exaggerated hypertensive response to dopamine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pergolide: May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists. Management: If possible, avoid coadministration of direct-acting alpha-/beta-agonists and serotonin/norepinephrine reuptake inhibitors. If coadministered, monitor for increased sympathomimetic effects (eg, increased blood pressure, chest pain, headache).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists. Management: Avoid, if possible, the use of alpha-/beta-agonists in patients receiving tricyclic antidepressants. If combined, monitor for evidence of increased pressor effects and consider reductions in initial dosages of the alpha-/beta-agonist.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vasopressin: Alpha-/Beta-Agonists (Direct-Acting) may enhance the hypertensive effect of Vasopressin. The effect of other hemodynamic parameters may also be enhanced. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F13314046"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Medications required for the treatment of critically ill pregnant patients should not be withheld due to concerns of fetal teratogenicity (ACOG 2019; AHA [Jeejeebhoy 2015]). Medications used for the treatment of cardiac arrest in pregnancy are the same as in the nonpregnant patients. Dopamine use during the postresuscitation phase may be considered; however, the effects of vasoactive medications on the fetus should also be considered. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines (AHA [Jeejeebhoy 2015]).</p></div>
<div class="block brc drugH1Div" id="F20306045"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if dopamine is present in breast milk.</p></div>
<div class="block mop drugH1Div" id="F162634"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> General monitoring parameters are below; individualize monitoring and consult institutional policies and procedures.</p>
<p style="text-indent:-2em;margin-left:2em;">BP, heart rate, ECG; hemodynamic parameters as appropriate (eg, CVP, RAP, CI, PCWP, SVR, ScvO<sub>2</sub> or SvO<sub>2</sub>); end-organ perfusion (eg, urine output, mental status); infusion site for blanching/extravasation; intravascular volume status.</p></div>
<div class="block pha drugH1Div" id="F162625"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Stimulates both adrenergic and dopaminergic receptors, lower doses are mainly dopaminergic stimulating and produce renal and mesenteric vasodilation, higher doses also are both dopaminergic and beta<sub>1</sub>-adrenergic stimulating and produce cardiac stimulation and renal vasodilation; large doses stimulate alpha-adrenergic receptors</p></div>
<div class="block phk drugH1Div" id="F162642"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Children: Dopamine has exhibited nonlinear kinetics in children; with dose changes, may not achieve steady-state for ~1 hour rather than 20 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Adults: Within 5 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Adults: &lt;10 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Renal, hepatic, plasma; 75% to inactive metabolites by monoamine oxidase and 25% to norepinephrine (active).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~2 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (as metabolites).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Neonates: Varies and appears to be age related; clearance is more prolonged with combined hepatic and kidney dysfunction.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F162646"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Dopamin | Dopamine | Dopmin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Dopamina duncan | Dopamina northia | Dopamina surar pharma | Dopatropin | Hettytropin | Inotropin | Megadose</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Dopamin | Dopamin ebewe | Dopamin Solvay</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Dopamine | Dopamine juno</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Cardopa | Dopamin | Myomine</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Dynatra</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Dopamin | Dopamin Admeda | Dopmin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloridrato de dopamina | Constriction | Dopabane | Dopacris | Dopamin | Dopamina | Dopamol | Inotropisa | Revimine | Revivan | Teudom</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Dopamin braun | Dopamin fresenius | Dopamin Giulini | Dopamin Sintetica</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Dopamine</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cardiopal | Dopamina | Dopamina clorhidrato | Doparis | Inotropisa | Myofast</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Dopamin | Dopamin Admeda</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Dopamin | Dopamin natter | Dopamin Solvay</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Dopamina</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Dopamina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Dopamin | Dopamina grifols | Dopamine | Dopamine wzf polfa | Dopmin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Dopamine | Dopasunny</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Aprical dopamida | Dopamina fides | Dopamina grifols</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Dopadren | Dopamine</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Abbodop | Dopmin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Dopamine aguettant | Dopamine lucien | Dopamine merck | Dopamine nativelle | Dopamine PCH | Dopamine pierre fabre | Dopamine Renaudin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Dopamine | Dopamine premix | Ims dopamine | Intropin | Intropin ahs</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Dopamine hycrochloride | Giludop</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Dopamin Giulini | Dopamin Solvay</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Cetadop | Dopac | Dopamin | Dopamin Giulini | Dopamine hcl abbott | Doperba | Indop | Oridop | Proinfark | Udopa</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Dopamine</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Domin | Dopacef | Dopacin | Dopamine | Dopamine-p | Dopan | Dopinga | Dopress</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Dopamina abbott | Dopamina cloridrato | Dopamina pht | Dopamina salf | Revivan</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Domine | Dopamine | Dopamine fresenius</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Actopamin | Catabon | Catherine | Catherine amel | Corskool | Critpan | Dasomin | Dolpamil | Dominin | Donapan | Doncal | Dopa kit | Dopamine | Dopamine hydrochloride kobayashi | Dopamine Hydrochloride Mochida | Dopamine Hydrochloride Shionogi | Dopamine towa | Dopaminex | Doparalmin | Elebumin | Evetant hexal | Evetant towa | Gabans | Inovan | Kakodin | Martburn | Mitasmin | Predopa | Predopa Kyowa | Predopa merck hoei | Seminiet | Taiadopa | Tronjin | Tsurudopami | Yaelista | Yaelista mita</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Dopamine hcl fresenius</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Domine | Domins | Dopamine | Dopamine injection huons | Dopaminex | Dopan | Dopasin | Dopramin | Inophan | Tropin | Udopa</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Dopamine | Intropin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Dopamine | Dopamine Renaudin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Dopamin | Dopamin Giulini | Dopmin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Dopamin | Dynatra</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Dopamin | Dopmin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Dopamina | Dopamina 3m | Dopamina exakta | Dopamina gi zafiro | Dopamina kendrick | Flemina | Inotropin | Inotropisa | Zetarina</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Dopaine | Dopamine | Dopmin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Dopamine | Dopaminehydrochloride Eureco Pharma | Dynatra</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Abbodop | Dopamin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Dopamine | Sterile dopamine concentrate</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Dopamina | Dopamina clorhidrato | Intropin</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Abbott dopamine hcl | Dopabas | Dopamax | Dopaqard | Dopnax | Doprina | Myocard | Myotil</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Dopamine | Dopasid | Dopna | Tropin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Dopamin Giulini | Dopaminum hydrochloricum</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Dopamine HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cordodopa | Cordodopa Forte | Dopamina | Dopamina basi | Medopa</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Dopamina duncan | Dopamina northia</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Dopadren | Dopasel | Myotil</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Clorhidrat de dopamina</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Dofamin | Dofamine | Dofamine Ferein | Dofamine n.s. | Dopamin | Dopamin Admeda | Dopamin Solvay | Dopamine | Dopmin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Domine | Dopamine | Dopamine HCL | Intropin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Giludop</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Dopamine</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Dopamin | Dopamin Admeda</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Dopamine</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Domin | Dopamex | Dopamin hausmann | Dopamine | Dopamine abbott | Dopamine HCL | Dopamine hydrochloride dbl | Dopaminex | Dopin | Dopmin | Inopin | Upamine</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Dopamine | Dopamine mylan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Dopadren | Dopamine | Dopamine fresenius | Dopasel | Dopmin | Giludop</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Dopamin | Dopamin Giulini | Dopamine | Dopamine HCL | Dopavate | Dopmin | Easydopa | Gipamine | Intropin | Revivan | Uramin | Vidopa</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Dofamin darnitsa | Dopamin | Dopamin Admeda | Dopmin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Dopamine hcl fresenius</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Bagotropin | Dopamin | Dopamina | Dopamina fu | Megadose</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dopamina | Dopina | Myotil</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Dopamine | Dopamine hcl fresenius | Micro Dopamine</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Pharma q dopamine</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Pharma q dopamine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-27969574">
<a name="27969574"></a>Adams C, Tucker C, Allen B, et al. Disparities in hemodynamic resuscitation of the obese critically ill septic shock patient. <i>J Crit Care</i>. 2017;37:219-223. doi:10.1016/j.jcrc.2016.10.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/27969574/pubmed" id="27969574" target="_blank">27969574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31022122">
<a name="31022122"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 211: Critical care in pregnancy. <i>Obstet Gynecol</i>. 2019;133(5):e303-e319. doi:10.1097/AOG.0000000000003241<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/31022122/pubmed" id="31022122" target="_blank">31022122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AHA.1">
<a name="AHA.1"></a>American Heart Association (AHA). CPR &amp; First Aid: Emergency Cardiovascular Care. Adult Bradycardia Algorithm. https://cpr.heart.org/en/resuscitation-science/cpr-and-ecc-guidelines/algorithms. Published 2020. Accessed January 29, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. Available at https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated January 2021. Accessed April 4, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23594407">
<a name="23594407"></a>Arabi YM, Dara SI, Tamim HM, et al; Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Clinical characteristics, sepsis interventions and outcomes in the obese patients with septic shock: an international multicenter cohort study. <i>Crit Care</i>. 2013;17(2):R72. doi:10.1186/cc12680<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/23594407/pubmed" id="23594407" target="_blank">23594407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15942351">
<a name="15942351"></a>Argalious M, Motta P, Khandwala F, et al. "Renal dose" dopamine is associated with the risk of new-onset atrial fibrillation after cardiac surgery. <i>Crit Care Med</i>. 2005;33(6):1327-1332.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/15942351/pubmed" id="15942351" target="_blank">15942351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26237037">
<a name="26237037"></a>Avni T, Lador A, Lev S, Leibovici L, Paul M, Grossman A. Vasopressors for the treatment of septic shock: systematic review and meta-analysis. <i>PLoS One</i>. 2015;10(8):e0129305. doi:10.1371/journal.pone.0129305<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/26237037/pubmed" id="26237037" target="_blank">26237037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11191541">
<a name="11191541"></a>Bellomo R, Chapman M, Finfer S, et al. Low-dose Dopamine in Patients With Early Renal Dysfunction: A Placebo-Controlled Randomised Trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. <i>Lancet</i>. 2000;356(9248):2139-2143.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/11191541/pubmed" id="11191541" target="_blank">11191541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26472996">
<a name="26472996"></a>Callaway CW, Donnino MW, Fink EL, et al. Part 8: Post-cardiac arrest care: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care [published correction appears in Circulation. 2017 Sep 5;136(10 ):e197]. <i>Circulation</i>. 2015;132(18 suppl 2):S465-S482. doi:10.1161/CIR.0000000000000262<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/26472996/pubmed" id="26472996" target="_blank">26472996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26014852">
<a name="26014852"></a>Cardenas-Garcia J, Schaub KF, Belchikov YG, Narasimhan M, Koenig SJ, Mayo PH. Safety of peripheral intravenous administration of vasoactive medication. <i>J Hosp Med</i>. 2015;10(9):581-5. doi:10.1002/jhm.2394<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/26014852/pubmed" id="26014852" target="_blank">26014852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7655133">
<a name="7655133"></a>Chan TY. Low-Dose Dopamine in Severe Right Heart Failure and Chronic Obstructive Pulmonary Disease. <i>Ann Pharmacother</i>. 1995;29(5):493-496.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/7655133/pubmed" id="7655133" target="_blank">7655133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24247300">
<a name="24247300"></a>Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. <i>JAMA</i>. 2013;310(23):2533-2543.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/24247300/pubmed" id="24247300" target="_blank">24247300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28509730">
<a name="28509730"></a>Davis AL, Carcillo JA, Aneja RK, et al. American College of Critical Care Medicine (ACCM) clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. <i>Crit Care Med</i>. 2017;45(6):1061-1093. doi:10.1097/CCM.0000000000002425<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/28509730/pubmed" id="28509730" target="_blank">28509730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22036860">
<a name="22036860"></a>De Backer D, Aldecoa C, Njimi H, et al. Dopamine versus Norepinephrine in the Treatment of Septic Shock: A Meta-Analysis. <i>Crit Care Med</i>. 2012;40(3):725-730.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/22036860/pubmed" id="22036860" target="_blank">22036860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20200382">
<a name="20200382"></a>De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. <i>N Engl J Med</i>. 2010;362(9):779-789.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/20200382/pubmed" id="20200382" target="_blank">20200382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23353941">
<a name="23353941"></a>Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. <i>Crit Care Med</i>. 2013;41(2):580-637. doi:10.1097/CCM.0b013e31827e83af<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/23353941/pubmed" id="23353941" target="_blank">23353941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31010560">
<a name="31010560"></a>Dempsey E, Rabe H. The use of cardiotonic drugs in neonates. <i>Clin Perinatol</i>. 2019;46(2):273-290. doi:10.1016/j.clp.2019.02.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/31010560/pubmed" id="31010560" target="_blank">31010560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2510208">
<a name="2510208"></a>Denkler KA, Cohen BE. Reversal of dopamine extravasation injury with topical nitroglycerin ointment. <i>Plast Reconstr Surg</i>. 1989;84(5):811-813.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/2510208/pubmed" id="2510208" target="_blank">2510208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Domonoske.1">
<a name="Domonoske.1"></a>Domonoske C. Appendix A: Common neonatal intensive care unit (NICU) medication guidelines. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th ed. Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AmericanRegent.1">
<a name="AmericanRegent.1"></a>Dopamine HCL injection solution [prescribing information]. Shirley, NY: American Regent Inc; March 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.1">
<a name="Hospira.1"></a>Dopamine Hydrochloride Injection (Fliptop, Pintop, LifeShield Fliptop Vials) [prescribing information]. Lake Forest, IL: Hospira; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.2">
<a name="Hospira.2"></a>Dopamine Hydrochloride in 5% Dextrose Injection [prescribing information]. Lake Forest, IL: Hospira; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18172028">
<a name="18172028"></a>Elkayam U, Ng TM, Hatamizadeh P, Janmohamed M, Mehra A. Renal Vasodilatory Action of Dopamine in Patients With Heart Failure: Magnitude of Effect and Site of Action. <i>Circulation</i>. 2008;117(2):200-205. <i>J Card Fail</i>. 2010;16(12):922-930.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/18172028/pubmed" id="18172028" target="_blank">18172028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33622380">
<a name="33622380"></a>Erstad BL, Barletta JF. Drug dosing in the critically ill obese patient: a focus on medications for hemodynamic support and prophylaxis. <i>Crit Care</i>. 2021;25(1):77. doi:10.1186/s13054-021-03495-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/33622380/pubmed" id="33622380" target="_blank">33622380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34605781">
<a name="34605781"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. <i>Crit Care Med</i>. 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/34605781/pubmed" id="34605781" target="_blank">34605781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.1">
<a name="Expert.1"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956217">
<a name="20956217"></a>Field JM, Hazinski MF, Sayre MR, et al. Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):640-656.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/20956217/pubmed" id="20956217" target="_blank">20956217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15809463">
<a name="15809463"></a>Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. <i>Ann Intern Med</i>. 2005;142(7):510-524.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/15809463/pubmed" id="15809463" target="_blank">15809463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15343024">
<a name="15343024"></a>Hollenberg SM, Ahrens TS, Annane D, et al. Practice Parameters for Hemodynamic Support of Sepsis in Adult Patients: 2004 Update. <i>Crit Care Med</i>. 2004;32(9):1928-1948.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/15343024/pubmed" id="15343024" target="_blank">15343024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21097695">
<a name="21097695"></a>Hollenberg SM. Vasoactive drugs in circulatory shock. <i>Am J Respir Crit Care Med</i>. 2011;183(7):847-855. doi:10.1164/rccm.201006-0972CI<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/21097695/pubmed" id="21097695" target="_blank">21097695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15192356">
<a name="15192356"></a>Hurst S, McMillan M. Innovative Solutions in Critical Care Units: Extravasation Guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/15192356/pubmed" id="15192356" target="_blank">15192356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network. Standard Concentrations of Neonatal Drug Infusions. 2011. https://www.ismp.org/Tools/PediatricConcentrations.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26443610">
<a name="26443610"></a>Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, Council on Clinical Cardiology. Cardiac arrest in pregnancy: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(18):1747-1773. doi:10.1161/CIR.0000000000000300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/26443610/pubmed" id="26443610" target="_blank">26443610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9679713">
<a name="9679713"></a>Johnson RL Jr. Low-Dose Dopamine and Oxygen Transport by the Lung. <i>Circulation</i>. 1998;98(2):97-99.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/9679713/pubmed" id="9679713" target="_blank">9679713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11505120">
<a name="11505120"></a>Kellum JA, Decker J. Use of Dopamine in Acute Renal Failure: A Meta-Analysis. <i>Crit Care Med</i>. 2001;29(8):1526-1531.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/11505120/pubmed" id="11505120" target="_blank">11505120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.2012">
<a name="KDIGO.2012"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. <i>Kidney Int</i>. 2012;2(suppl 1):1-138. http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO%20AKI%20Guideline.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956230">
<a name="20956230"></a>Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):S876-S908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/20956230/pubmed" id="20956230" target="_blank">20956230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30412709">
<a name="30412709"></a>Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2019;74(7):e51-e156. doi:10.1016/j.jacc.2018.10.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/30412709/pubmed" id="30412709" target="_blank">30412709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32049269">
<a name="32049269"></a>Lamontagne F, Richards-Belle A, Thomas K, et al; 65 trial investigators. Effect of reduced exposure to vasopressors on 90-day mortality in older critically ill patients with vasodilatory hypotension: a randomized clinical trial. <i>JAMA</i>. 2020;323(10):938–49. doi:10.1001/jama.2020.0930<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/32049269/pubmed" id="32049269" target="_blank">32049269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29767636">
<a name="29767636"></a>Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 Update. <i>Crit Care Med</i>. 2018;46(6):997-1000. doi: 10.1097/CCM.0000000000003119<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/29767636/pubmed" id="29767636" target="_blank">29767636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28073314">
<a name="28073314"></a>Lewis T, Merchan C, Altshuler D, Papadopoulos J. Safety of the peripheral administration of vasopressor agents. <i>J Intensive Care Med</i>. 2019;34(1):26-33. doi:10.1177/0885066616686035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/28073314/pubmed" id="28073314" target="_blank">28073314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manaker.1">
<a name="Manaker.1"></a>Manaker S. Use of vasopressors and inotropes. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 22, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8404107">
<a name="8404107"></a>Martin C, Papazian L, Perrin G, et al. Norepinephrine or Dopamine for the Treatment of Hyperdynamic Septic Shock? <i>Chest.</i> 1993;103(6):1826-1831.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/8404107/pubmed" id="8404107" target="_blank">8404107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29110979">
<a name="29110979"></a>Medlej K, Kazzi AA, El Hajj Chehade A, et al. Complications from administration of vasopressors through peripheral venous catheters: an observational study. <i>J Emerg Med</i>. 2018;54(1):47-53. doi:10.1016/j.jemermed.2017.09.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/29110979/pubmed" id="29110979" target="_blank">29110979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25147175">
<a name="25147175"></a>Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. <i>Am J Health Syst Pharm</i>. 2014;71(17):1500-1508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/25147175/pubmed" id="25147175" target="_blank">25147175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956224">
<a name="20956224"></a>Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):S729-S767.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/20956224/pubmed" id="20956224" target="_blank">20956224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33081529">
<a name="33081529"></a>Panchal AR, Bartos JA, Cabañas JG, et al; Adult Basic and Advanced Life Support Writing Group. Part 3: adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2020;142(16)(suppl 2):S366-S468. doi:10.1161/CIR.0000000000000916<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/33081529/pubmed" id="33081529" target="_blank">33081529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19851126">
<a name="19851126"></a>Patel GP, Grahe JS, Sperry M, et al. Efficacy and Safety of Dopamine versus Norepinephrine in the Management of Septic Shock. <i>Shock</i>. 2010;33(4):375-380.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/19851126/pubmed" id="19851126" target="_blank">19851126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956225">
<a name="20956225"></a>Peberdy MA, Callaway CW, Neumar RW, et al. Part 9: Post Cardiac Arrest Care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):768-786.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/20956225/pubmed" id="20956225" target="_blank">20956225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22058104">
<a name="22058104"></a>Phillips MS. Standardizing I.V. Infusion Concentrations: National Survey Results. <i>Am J Health Syst Pharm</i>. 2011;68(22):2176-2182.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/22058104/pubmed" id="22058104" target="_blank">22058104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33049486">
<a name="33049486"></a>Prasanna N, Yamane D, Haridasa N, Davison D, Sparks A, Hawkins K. Safety and efficacy of vasopressor administration through midline catheters. <i>J Crit Care</i>. 2021;61:1-4. doi:10.1016/j.jcrc.2020.09.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/33049486/pubmed" id="33049486" target="_blank">33049486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26724290">
<a name="26724290"></a>Radosevich JJ, Patanwala AE, Erstad BL. Norepinephrine dosing in obese and nonobese patients with septic shock. <i>Am J Crit Care</i>. 2016;25(1):27-32. doi:10.4037/ajcc2016667<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/26724290/pubmed" id="26724290" target="_blank">26724290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, Maclaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28101605">
<a name="28101605"></a>Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377. doi:10.1007/s00134-017-4683-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/28101605/pubmed" id="28101605" target="_blank">28101605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32820475">
<a name="32820475"></a>Russell JA, Gordon AC, Williams MD, Boyd JH, Walley KR, Kissoon N. Vasopressor therapy in the intensive care unit. <i>Semin Respir Crit Care Med</i>. 2021;42(1):59-77. doi:10.1055/s-0040-1710320<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/32820475/pubmed" id="32820475" target="_blank">32820475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16505643">
<a name="16505643"></a>Sakr Y, Reinhart K, Vincent JL, et al. Does Dopamine Administration in Shock Influence Outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. <i>Crit Care Med</i>. 2006;34(3):589-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/16505643/pubmed" id="16505643" target="_blank">16505643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy.</i> 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9928712">
<a name="9928712"></a>Stier PA, Bogner MP, Webster K, et al. Use of Subcutaneous Terbutaline to Reverse Peripheral Ischemia. <i>Am J Emerg Med</i>. 1999;17(1):91-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/9928712/pubmed" id="9928712" target="_blank">9928712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31698544">
<a name="31698544"></a>Tian DH, Smyth C, Keijzers G, et al. Safety of peripheral administration of vasopressor medications: a systematic review. <i>Emerg Med Australas</i>. 2020;32(2):220-227. doi:10.1111/1742-6723.13406<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/31698544/pubmed" id="31698544" target="_blank">31698544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7568905">
<a name="7568905"></a>Tisdale JE, Patel R, Webb CR, Borzak S, Zarowitz BJ. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. <i>Prog Cardiovasc Dis</i>. 1995;38(2):167-180.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/7568905/pubmed" id="7568905" target="_blank">7568905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24485633">
<a name="24485633"></a>Triposkiadis FK, Butler J, Karayannis G, et al. Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: The Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial. <i>Int J Cardiol</i>. 2014;172(1):115-121.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/24485633/pubmed" id="24485633" target="_blank">24485633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27886982">
<a name="27886982"></a>Vadiei N, Daley MJ, Murthy MS, Shuman CS. Impact of norepinephrine weight-based dosing compared with non-weight-based dosing in achieving time to goal mean arterial pressure in obese patients with septic shock. <i>Ann Pharmacother</i>. 2017;51(3):194-202. doi:10.1177/1060028016682030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/27886982/pubmed" id="27886982" target="_blank">27886982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9679718">
<a name="9679718"></a>van de Borne P, Oren R, Somers VK. Dopamine Depresses Minute Ventilation in Patients With Heart Failure. <i>Circulation</i>. 1998;98(2):126-131.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/9679718/pubmed" id="9679718" target="_blank">9679718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28923988">
<a name="28923988"></a>van Diepen S, Katz JN, Albert NM, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. <i>Circulation</i>. 2017;136(16):e232-e268. doi:10.1161/CIR.0000000000000525<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/28923988/pubmed" id="28923988" target="_blank">28923988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956228">
<a name="20956228"></a>Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):S836.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/20956228/pubmed" id="20956228" target="_blank">20956228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21436167">
<a name="21436167"></a>Vasu TS, Cavallazzi R, Hirani A, et al. Norepinephrine or Dopamine for Septic Shock: Systematic Review of Randomized Clinical Trials. <i>J Intensive Care Med</i>. 2012;27(3):172-178.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/21436167/pubmed" id="21436167" target="_blank">21436167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32032273">
<a name="32032273"></a>Weiss SL, Peters MJ, Alhazzani W, et al. Surviving Sepsis Campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. <i>Pediatr Crit Care Med</i>. 2020;21(2):e52-e106. doi:10.1097/PCC.0000000000002198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/32032273/pubmed" id="32032273" target="_blank">32032273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1447671">
<a name="1447671"></a>Wong AF, McCulloch LM, Sola A. Treatment of Peripheral Tissue Ischemia With Topical Nitroglycerin Ointment in Neonates. <i>J Pediatr</i>. 1992;121(6):980-983.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/1447671/pubmed" id="1447671" target="_blank">1447671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11016488">
<a name="11016488"></a>Young JB, Moen EK. Outpatient parenteral inotropic therapy for advanced heart failure. <i>J Heart Lung Transplant</i>. 2000;19(8)(suppl):s49-s57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/11016488/pubmed" id="11016488" target="_blank">11016488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16935995">
<a name="16935995"></a>Zipes DP, Camm AJ, Borggrefe M, et al; American College of Cardiology/American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. <i>Circulation</i>. 2006;114(10):e385-e484.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/16935995/pubmed" id="16935995" target="_blank">16935995</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9384 Version 283.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
